In vivo gene delivery refers to introducing genetic material directly into a living organism’s cells, rather than manipulating cells outside the body (ex vivo), to achieve therapeutic gene expression in target tissues for disease treatment, prevention, or modification.
Core Approaches
A. Viral Vectors
- Adeno-associated virus (AAV): High tissue specificity, low immunogenicity
- Lentivirus: Integrates into host genome, longer expression
- Adenovirus: High expression, transient, more immunogenic
Advantages:
- High efficiency
- Targeted expression
- Clinical precedence (approved gene therapies)
Limitations:
- Immune response
- Packaging size limits
- Manufacturing complexity
B. Non-Viral Delivery
- Lipid nanoparticles (LNPs): Encapsulate mRNA or plasmid DNA; widely used in mRNA vaccines
- Polymeric nanoparticles: Cationic polymers bind DNA/RNA
- Physical methods: Electroporation, hydrodynamic injection, microinjection
Advantages:
- Lower immunogenicity
- Flexible payload size
- Scalable manufacturing
Limitations:
- Lower efficiency vs viral
- Tissue targeting can be challenging
- Stability in vivo
C. Physical Targeting / Tissue-Specific Delivery
- Targeting ligands, antibodies, or peptides can be added to vectors to home in on specific cell types
- Examples: hepatocyte-targeted AAV, immune cell-targeted nanoparticles
Applications in Gene Editing
In vivo delivery is crucial for therapeutic gene editing platforms, including:
- CRISPR-Cas9 / Base Editing / Prime Editing in organs like liver, muscle, or retina
- RNA editing therapeutics delivered via LNPs
- Epigenetic modulation by dCas9-effector complexes
Key challenge:
- Deliver the editing machinery efficiently without triggering toxicity, immune response, or off-target effects.
IP Perspective
In vivo gene delivery is highly patentable because patents often focus on:
- Vector composition and design
- Capsid modifications, promoter sequences, payload design
- Delivery methods
- Routes of administration (intravenous, intramuscular, intrathecal)
- Formulation techniques for stability and targeting
- Targeting specificity
- Ligands, receptor-mediated uptake
- Tissue- or cell-type selectivity
- Combination with gene editing platforms
- Cas9/base editors/prime editors + delivery vehicle
Why it’s IP-rich:
- Small variations in delivery method, vector, or formulation can create new patentable inventions.
- Many patent disputes hinge on efficiency, tissue targeting, and safety metrics.
BioTech IP Review 
Leave a comment